NRX Pharmaceuticals Inc
NRXP
Company Profile
Business description
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Contact
1201 Orange Street
Suite 600
WilmingtonDE19801
USAT: +1 484 254-6134
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
Stocks News & Analysis
stocks
Earnings losers: TWE, GMG, SUN and more fall on weaker profits
Where companies fell short of market expectations in the third week of earnings.
stocks
ASX healthcare leader still undervalued after rally
Our view following announcement of potential spinoff.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,249.90 | 84.70 | -0.91% |
| CAC 40 | 8,515.49 | 116.71 | 1.39% |
| DAX 40 | 25,260.69 | 217.12 | 0.87% |
| Dow JONES (US) | 49,588.98 | 193.82 | 0.39% |
| FTSE 100 | 10,686.89 | 59.85 | 0.56% |
| HKSE | 26,992.69 | 579.34 | 2.19% |
| NASDAQ | 22,875.73 | 193.00 | 0.85% |
| Nikkei 225 | 56,825.70 | 642.13 | -1.12% |
| NZX 50 Index | 13,361.76 | 53.24 | 0.40% |
| S&P 500 | 6,905.36 | 43.47 | 0.63% |
| S&P/ASX 200 | 9,024.60 | 85.50 | -0.94% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |